Search

Copyright of Practical Pharmacy & Clinical Remedies is the property of Editorial Department of Practical Pharmacy & Clinical Remedies and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective To explore the effectiveness and safety of belimumab in Chinese adult lupus nephritis (LN) patients under a real-world setting. Methods For this retrospective cohort study, 30 LN patients received belimumab plus standard of care (SoC) due to a new onset or a relapse of LN from June 2021 to December 2022. And 30 matched patients only treated with SoC after propensity score matching (PSM) at the same period were also enrolled. After 24-week follow-ups, renal complete remission (CR), disease activity index, 24 h urine protein level, dose of prednisone and incidence of adverse events were compared. Results No statistically significant differences existed in baseline demographics, complement C3/C4, anti-dsDNA autoantibody titer, 24 h urine protein level or disease activity index. At Week 24, 21/30 patients achieved renal CR and it was higher than that of SoC group (21 vs 12, P=0.037). As compared with SoC group, belimumab group had lower levels of 24 h urine protein[346.50(183.75，571.00) mg vs 611.50(360.00，1450.00) mg], SLEDAI-2K (SLE disease activity index, SLEDAI-2K) score[(3.93±2.79) vs (5.70±3.14)] and daily prednisone dose [(11.67±4.34) mg/d vs (22.42±9.23) mg/d](P＜0.05). Furthermore, the incidence of adverse events between two group was comparable (P>0.05). Conclusions Belimumab plus SoC may alleviate LN, boost the rate of renal CR, lower 24 h urine protein levels, improve disease activity and reduce the intake of prednisone.

Objective To investigate the 12-month renal remission in patients with lupus nephritis (LN) and the predictive factors. Methods The remission of patients with LN using biologic agents was analyzed by a prospective cohort study that included 57 patients with LN and positive urine protein, who were divided into hormone + immunosuppression group (n=39) and hormone + immunosuppression + biologics group (n=18) . Patients in hormone + immunosuppression group received standard therapy and those in hormone + immunosuppression + biologics group received standard therapy and belimumab. Long-term follow-up was assigned to collect and analyze data on renal response and clinical characteristics. Results Renal complete remission was achieved in 41 out of 57 patients (71.93%) and partial remission was achieved in 16 patients (28.07%) . Complete remission was achieved in 29 out of 39 patients in the hormone + immunosuppression group (mean time to complete remission was 7.846 months, 95%CI: 6.626-9.066 months) and in 12 out of 18 patients in the hormone + immunosuppression + biologics group (mean time to complete remission was 4.167 months, 95%CI: 3.461-4.872 months) .Conclusion Patients using both hormones, immune agents and biologics achieve complete remission more quickly than those using only hormones and immune agents. [ABSTRACT FROM AUTHOR]

Copyright of Practical Pharmacy & Clinical Remedies is the property of Editorial Department of Practical Pharmacy & Clinical Remedies and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

OBJECTIVE: To systematically review the risk of severe infection in patients with systemic lupus erythematosus treated with belimumab. METHODS: Clinical randomized controlled trials (RCT) on belimumab in the treatment of systemic lupus erythematosus were retrieved from PubMed, the Cochrane Library, SinoMed, Ovid Embase, VIP, CNKI, Wanfang Data and other database (with a search deadline of Jul. 1st, 2022). Literature screening was performed in combination with the inclusion and exclusion criteria developed for this study, and data analysis was performed by using RevMan 5. 3 software to calculate the relative risk (RD) and their 95%CI for the risk of severe infections. RESULTS: Totally 9 clinical RCT were enrolled, including 5 174 patients. Results of Meta-analysis indicated that no statistically significant difference in the risk of serious infection between the group of belimumab combined with standard therapy and the group of placebo combined with standard therapy (RD = -0. 00, 95%CI = - 0. 01-0. 01, P = 0. 89). CONCLUSIONS: For patients with systemic lupus erythematosus, the risks of severe infection with belimumab combined with standard therapy was comparable to that with placebo combined with standard therapy; the combination of belimumab on the basis of standard therapy did not increase the risk of severe infection. [ABSTRACT FROM AUTHOR]

Copyright of Practical Pharmacy & Clinical Remedies is the property of Editorial Department of Practical Pharmacy & Clinical Remedies and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Contemporary Pediatrics is the property of Xiangya Medical Periodical Press and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Systemic lupus erythematosus (SLE) is an autoimmune disease involving multiple organs, and lupus nephritis (LN) is the most common renal complication of SLE. Belimumab is a fully humanized monoclonal antibody that can reduce the number of B cells, thereby reducing the formation of autoantibodies. Belimumab can improve SLE response index and SLE disease activity score and delay the progression of LN in both adults and children and thus plays an important role in the treatment of SLE and LN. This article reviews related research reports of belimumab used in the treatment of children and adults with SLE in China and overseas and analyzes the efficacy and safety of belimumab in pediatric patients, in order to provide a reference for the clinical application of belimumab in children with SLE.